Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity. This review synthesizes emerging mechanistic evidence showing that ...
Cancer immunotherapy has transformed cancer treatment, yet many patients experience limited or short-lived responses due to immune evasion, tumor heterogeneity, and immune-related adverse events.
Analysis of primary and acquired resistance to cetuximab from multiomic data in the New EPOC trial. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not include ...
News organizations may use or redistribute this image, with proper attribution, as part of news coverage of this paper only.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results